BLCM Stock - Bellicum Pharmaceuticals, Inc.
Unlock GoAI Insights for BLCM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $1.50M | $6.20M | $500,000 | $7.14M | $1.12M |
| Gross Profit | $1.50M | $6.20M | $500,000 | $7.14M | $1.12M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-26,981,000 | $-24,866,000 | $-51,692,000 | $-87,364,000 | $-95,466,000 |
| Net Income | $-24,973,000 | $-9,578,000 | $-8,619,000 | $-126,092,000 | $-98,036,000 |
| Net Margin | -1664.9% | -154.5% | -1723.8% | -1765.3% | -8753.2% |
| EPS | $-0.81 | $-0.83 | $-1.50 | $-26.92 | $-24.37 |
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Visit WebsiteEarnings History & Surprises
BLCMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 14, 2023 | — | $-0.02 | — | — |
Q3 2023 | Aug 10, 2023 | $-0.29 | $-0.24 | +17.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.34 | $-0.26 | +23.5% | ✓ BEAT |
Q1 2023 | Mar 24, 2023 | $-0.93 | $-0.27 | +71.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.64 | $-0.23 | +64.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.69 | $-0.13 | +81.2% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.67 | $-0.25 | +62.7% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.40 | $-0.27 | +32.5% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | — | $0.07 | — | — |
Q3 2021 | Aug 12, 2021 | $-1.37 | $-0.22 | +83.9% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-1.37 | $-0.89 | +35.0% | ✓ BEAT |
Q1 2021 | Mar 30, 2021 | — | $-3.05 | — | — |
Q4 2020 | Nov 5, 2020 | $-3.29 | $-2.58 | +21.6% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-3.33 | $-2.47 | +25.8% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-2.73 | $1.09 | +139.9% | ✓ BEAT |
Q1 2020 | Mar 12, 2020 | $-4.90 | $-2.94 | +40.0% | ✓ BEAT |
Q4 2019 | Nov 6, 2019 | $-5.70 | $-5.80 | -1.8% | ✗ MISS |
Q3 2019 | Aug 5, 2019 | $-5.40 | $-5.80 | -7.4% | ✗ MISS |
Q2 2019 | May 7, 2019 | $-5.60 | $-5.50 | +1.8% | ✓ BEAT |
Q1 2019 | Mar 12, 2019 | $-5.90 | $-6.30 | -6.8% | ✗ MISS |
Latest News
Frequently Asked Questions about BLCM
What is BLCM's current stock price?
What is the analyst price target for BLCM?
What sector is Bellicum Pharmaceuticals, Inc. in?
What is BLCM's market cap?
Does BLCM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BLCM for comparison